Press Release

Electrotherapy: Medical Company Medical Company Leaders MedTronic PLC (NYSE: MDT), Electromedical Technologies, Inc. (OTCQB: EMED) And Abbott Laboratories (NYSE: ABT) Offer Solutions for Chronic Pain

Electrotherapy: Medi

iCrowdNewswire   Nov 4, 20208:15 AM ET

COVID-19 Pandemic Inflames Chronic Pain, Everything From Mental Health To Opioid Addiction, Quickening Development Of Treatments Including Electrotherapy Via Device-Based Medical Therapies To New Pharmaceuticals; Medical Company Leaders MedTronic PLC (NYSE: MDT),  Electromedical Technologies, Inc. (OTCQB: EMED) And Abbott Laboratories (NYSE: ABT) Offer Solutions

Medical company leaders are in a race to offer new therapies, OTC and prescription drugs, and devices to battle COVID-19 inflamed chronic pain and opioid addiction. Patients are delaying medical appointments, suffering from everything from bad backs to mental health ailments, as the pandemic drags on. Companies such as MedTronic PLC (NYSE: MDT), Electromedical Technologies, Inc. (OTCQB: EMED) And Abbott Laboratories (NYSE: ABT) are developing new devices and pharmaceuticals.

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT),  Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM).  GlaxoSmithKline (NYSE: GSK),  Abbott Laboratories (NYSE: ABT), Eli Lilly (NYSE: LLY),  Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

COVID-19 Pandemic Inflames Chronic Pain, Everything From Mental Health To Opioid Addiction, Quickening Development Of Treatments Including Electrotherapy Via Device-Based Medical Therapies To New Pharmaceuticals; Medical Company Leaders MedTronic PLC (NYSE: MDT),  Electromedical Technologies, Inc. (OTCQB: EMED) And Abbott Laboratories (NYSE: ABT) Offer Solutions

Dr. Marcia Ward said of chronic and acute pain made worse by the pandemic, “Unfortunately, the COVID-19 pandemic has disrupted treatments for people with pain because regular out-patient appointments with doctors and physical therapists have had to be canceled or postponed.”

Research firm Prescient & Strategic Intelligence sees the chronic pain treatment market hitting $151.7 Billion by 2030, reflecting a CAGR of 6.5%% during the forecast period from 2020-2030. The pandemic accelerated the opioid epidemic crisis in the research period. The report finds that North America dominates the global chronic pain market. COVID-19 Pandemic Inflames Chronic Pain, Everything From Mental Health To Opioid Addiction, Quickening Development Of Treatments Including Electrotherapy Via Device-Based Medical Therapies To New Pharmaceuticals; Medical Company Leaders MedTronic PLC (NYSE: MDT),  Electromedical Technologies, Inc. (OTCQB: EMED) And Abbott Laboratories (NYSE: ABT) Offer Solutions.

Electromedical Technologies, Inc. (OTCQB: EMED) Planning Wellness Pro® Pod.

As chronic and acute pain made worse by the COVID-19 pandemic, medical company leaders are developing new solutions and preparing to launch new devices.  Electromedical Technologies, Inc. (OTCQB: EMED) is a commercial-stage company marketing a line of FDA cleared devices for the treatment of chronic acute post-traumatic and post-operative, intractable pain relief. Its WellnessPro™Plus device treats chronic and acute pain. The Company is planning to launch another device: the Wellness Pro® Pod. It is collaborating with universities and colleges to establish a comprehensive research program that defines the effects of electro-modulation on the human body — especially cell signaling and its effects on virus assembly and immune responses.

MedTronic PLC (NYSE: MDT) has developed a drug infusion system for chronic pain including its PTM™ Personal Therapy Manager works with the SynchroMed™ II Pump to help alleviate unpredictable pain by enabling on-demand intrathecal boluses. It is designed to help eliminate the need to treat unpredictable pain with systematic medication. COVID-19 Pandemic Inflames Chronic Pain, Everything From Mental Health To Opioid Addiction, Quickening Development Of Treatments Including Electrotherapy Via Device-Based Medical Therapies To New Pharmaceuticals; Medical Company Leaders MedTronic PLC (NYSE: MDT),  Electromedical Technologies, Inc. (OTCQB: EMED) And Abbott Laboratories (NYSE: ABT) Offer Solutions.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company, has in its product pipeline AXS-05 which is in its phase III clinical trial for the treatment of resistant depression and depressive disorders. It is also in phase II/III clinical trials in agitation associated with Alzheimer’s disease. Additionally, it is also in Phase III clinical trials for Phase III clinical trials for the treatment of migraine.

Novartis AG (NYSE: NVS) has an expanding presence in Specialty Neurology, including a portfolio of products, in developing a portfolio of products in development for migraine and neuropathic pain. The Company is also developing treatments and medicines/therapies for the treatment of Alzheimer’s disease. COVID-19 Pandemic Inflames Chronic Pain, Everything From Mental Health To Opioid Addiction, Quickening Development Of Treatments Including Electrotherapy Via Device-Based Medical Therapies To New Pharmaceuticals; Medical Company Leaders MedTronic PLC (NYSE: MDT),  Electromedical Technologies, Inc. (OTCQB: EMED) And Abbott Laboratories (NYSE: ABT) Offer Solutions.

Eli Lilly (NYSE: LLY) has a separate division for developing pain management. It focuses on COVID-19, developing new medicines to treat pain, and is cautious about opioids for treating migraines. The results can be opioid-addiction. Eli Lilly is seeking to develop treatments for neuropathic pain.

Abbott Laboratories (NYSE: ABT) has developed FDA approval for its XR SCS System to help treat patients with intractable chronic pain located in the trunk and/or limbs. GlaxoSmithKline (NYSE: GSK) received FDA approval for its Voltaren Arthritis Pain medication as an OTC product. It was the first prescription-strength NSAID topical get available OTC in the U.S. The product offers temporary relief from arthritis pain in areas such as the knee, elbow, arm, foot, and ankle.

Source: Stock Market Press

Join Stock Market Press’ newsletter for the latest in IPO, market commentary, and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists, and the general public via social media and a rapidly expanding network.

Contact Information:

Electromedical Technologies, Inc.
Matthew Wolfson
Tel: 1.888.880.7888
email: [email protected]
www.electromedtech.com


iCrowdNewswire

Keywords:    Stocks, Covid-19, Nasdaq, Stockmarket, Portfolio, Medical.

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *